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Abstract
Background—Despite development of current targeted therapies for medullary thyroid cancer
(MTC), long-term survival remains unchanged. Recently isolated novel withanolide compounds
from Solanaceae physalis are highly potent against MTCs. We hypothesize that these withanolides
uniquely inhibit RET phosphorylation and the mammalian target of rapamycin (mTOR) pathway
in MTC cells as a mechanism of antiproliferation and apoptosis.
Methods—MTC cells were treated with novel withanolides and MTC-targeted drugs. In vitro
studies assessed cell viability and proliferation (MTS; trypan blue assays), apoptosis (flow
cytometry with Annexin V/PI staining; confirmed by Western blot analysis), long-term cytotoxic
effects (clonogenic assay), and suppression of key regulatory proteins such as RET, Akt, and
mTOR (by Western blot analysis).
Results—The novel withanolides potently reduced MTC cell viability (half maximal inhibitory
concentration [IC50], 270–2,850 nmol/L; 250–1,380 nmol/L for vandetanib; 360–1,640 nmol/L for
cabozantinib) with induction of apoptosis at <1,000 nmol/L of drug. Unique from other targeted
therapies, withanolides suppressed RET and Akt phosphorylation and protein expression (in a
concentration- and time-dependent manner) as well as mTOR activity and translational activity of
4E-BP1 and protein synthesis mediated by p70S6kinase activation at IC50 concentrations.
Conclusion—Novel withanolides from Physalis selectively and potently inhibit MTC cells in
vitro. Unlike other MTC-targeted therapies, these compounds uniquely inhibit both RET kinase
activity and the Akt/mTOR prosurvival pathway. Further translational studies are warranted to
evaluate their clinical potential.
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Although the incidence of medullary thyroid cancer (MTC) has grown each year, recently
>2,200 new cases reported in the United States in 2010,1 survival statistics in this disease
have not significantly improved over the last 3 decades, warranting novel therapies with
better efficacy. For early stage disease confined to the thyroid or locoregional nodes, 5-year
disease-specific survival rates have been reported at >80%; however, once tumors
metastasize systemically, survival drops significantly to <55%.2,3 Operative resection is the
standard of care for local disease and recurrence; however, >50% of patients recur or
progress despite optimal operative resection.2
Standard chemotherapy regimens have limited efficacy in poorly differentiated thyroid
cancers such as MTC. Response rates are often temporary and occur in <10–20% of patients
and are without long-term benefit. Additionally, these drugs carry systemic toxicities that
can be dose limiting.4 Recently, targeted therapies developed on the genetic and molecular
basis of MTCs have led to several Phase I, II, and III human trials worldwide. Because a
majority of MTCs are owing to mutations of the RET protooncogene (which encodes a
transmembrane tyrosine kinase receptor),3,5,6 a number of tyrosine kinase inhibitors (TKI)
and multikinase inhibitors have been developed in the last decade, including RET-kinase–
specific inhibitors that share the property of binding to the RET/ATP-binding pocket. These
TKIs that target RET include drugs such as vandetanib, sorafenib, sunitinib, imatinib,
axitinib, motesanib, gefitinib, and cabozantinib (XL184).7–9 Although these drugs may
stabilize disease progression in many patients, they lack durable, long-term responses and
carry moderate systemic toxicity for many patients. Opportunities, therefore, remain to
identify novel durable therapies for advanced MTC.
Natural products continue to play a highly significant role in the drug discovery and
development process, particularly in the area of cancer therapeutics, where a majority of the
most widely used cytotoxic agents are of natural origin. Several genera in the large plant
family Solanaceae produce compounds called withanolides, of which the most important
and well-described is the steroidal lactone, withaferin A (WA).10,11 The withanolides exert a
number of different effects including anti-stress, anti-inflammatory, and cytotoxic activities;
however, their role as anticancer agents in MTC is currently being investigated.12,13
WA isolated from the Withania somnifera plant has been shown to significantly inhibit
MTC tumor mass in vivo in a metastatic mouse model.14,15 In addition to induction of
apoptosis and inhibition of the PI3kinase/Akt pathway by WA in thyroid cancers, WA has
also been reported to inhibit Notch signaling and the mammalian target of rapamycin
(mTOR) pathway in colon cancer cells.16 In the present study, the anti-cancer activity of
several novel withanolides will be examined in MTC cells and compared with WA and TKIs
used in MTC clinical trials such as 17-AAG, axitinib, vandetanib, and cabozantinib. We
hypothesize that novel withanolide derivatives, unlike other targeted kinase inhibitors,
uniquely inhibit MTC cell proliferation and induce apoptosis through a combination of RET
kinase inhibition as well as inhibition of the Akt/mTOR signaling pathway.
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Reagents and cell culture
All chemical reagents were obtained from Sigma Chemical Co (St. Louis, MO) unless
specified otherwise. Antibodies to phospho-Thr-389 S6K, phospho-Thr-36/47 4E-BP1,
phospho-Ser-65 4E-BP1, 4E-BP1, phospho-mTOR, mTOR, phospho-Akt, Akt, phospho-
ERK, ERK, phospho-p70S6K, p70S6K, caspase 3, and PARP from Cell Signaling
Technology (Beverly, MA); antibodies to actin from Millipore (Temecula, CA), and
horseradish peroxidase-labeled anti-mouse, anti-goat, and anti-rabbit secondary antibodies
from Santa Cruz Biotechnology (Santa Cruz, CA). The human MTC cell lines included
MTC-TT cells (derived from MEN2A patient with codon 634 mutation) obtained from
ATCC (Manassas, VA) and DRO 81-1 cells (derived from a patient with sporadic MTC)
were provided by Dr Guy Juillard (University of California, Los Angeles, CA). The
papillary thyroid cancer cell-line, TPC 1 (with a RET/PTC mutation), was provided by Dr
Sissy M. Jhiang (Ohio State University, Columbus, OH). DRO81-1 and TPC 1 cancer cell
lines were grown in RPMI 1640 medium (Sigma) supplemented with 2 g/L sodium
bicarbonate, 0.14 mmol/L nonessential amino acids, 1.4 mmol/L sodium pyruvate, and 10%
fetal bovine serum at a constant temperature of 37°C with a humidified atmosphere of 5%
carbon dioxide (CO2). TT cells were cultured in RPMI 1640 medium supplemented with 2
mmol/L L-glutamine, 1.5 g/L sodium bicarbonate, and 15% fetal bovine serum. The cells
were passaged twice a week. For growth experiments, cells were trypsinized and cells were
cultured overnight before treatment. Control cultures were incubated in medium containing
vehicle alone. Drug compounds utilized for these experiments included WA, the novel
withanolides withalongolide A [19-hydroxy withaferin A (WGA; also referenced as
compound X001), withalongolide A 4,19,27-triacetate (WGA-TA; also referenced as
compound X003), withalongolide D (WGD; also referenced as compound X005),
withalongolide B 4-acetate (WGB-MA; also referenced as compound X032), withalongolide
B 4,19-diacetate (WGB-DA; also referenced as compound X033), all obtained from Dr
Barbara Timmermann’s laboratory (Lawrence, KS). Additional drugs included several TKIs
used in MTC trials. Axitinib (Cat # A-1107), vandetanib (Cat # V-9402), and 17-AAG (Cat
# A-6880) were obtained from LC Laboratories (Woburn, MA); cabozantinib (XL184) (Cat
# S1119) was obtained from SelleckChem (Houston, TX).
Cell growth assay
Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS) dye-reduction assay
(Promega, Madison, WI) measuring mitochondrial respiratory function according to the
manufacturer’s instruction. MTC cells (2–5 × 103/well) were plated in 96-well microtitre
plates and treated with drugs at various concentrations (0.03–20 mmol/L) for 72 hours. Cells
were then incubated with MTS dye (2 mg/mL per 20 μL/well) for 2 hours. Absorbance was
determined in a Biotek plate reader at 490 nm. The absorbance is directly related to viable
cell number.
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For cell cycle studies, DRO81-1 cells (105 cells) in 60-mm plates were exposed to
withanolides for 24 and 48 hours. After cells were washed, DNA was stained with 50 μg/mL
propidium iodide (PI) solution (0.02 μg/μL RNase A, 1.0 mg/mL sodium citrate-dihydrate,
0.1 μg/μL PI, 0.3% Triton X-100) at 25°C for 30 minutes. For fluorescence-activated cell
sorting analysis, the FACS-can (Becton Dickinson, Franklin Lakes, NJ) was used. Cell-cycle
analysis was performed with the use of ModFit LT software (Verity Software House, Inc,
Topsham, ME). For Annexin V/PI studies, cells were washed after treatment and were
collected by trypsinization. Cells were washed twice with 1 × phosphate-buffered saline
(PBS) and then stained with Annexin V-FITC and PI according to the manufacturer’s
instruction (BD Bioscience, San Jose, CA).
Western blot analysis
After treatment, DRO81-1 cells were lysed with ice-cold lysis buffer [150 mmol/L NaCl, 40
mmol/L HEPES (pH 7.4), 2 mmol/L EGTA, 2.5 mmol/L MgCl2, 1% Triton X-100, and 1X
EDTA-free protease inhibitors (Sigma)]. The soluble fractions from cell lysates were
isolated by centrifugation at 14,000 rpm for 20 minutes in a microfuge. Protein
concentration was determined by bicinchoninic acid protein assay kit according to the
manufacturer’s instructions (Pierce Biotechnology, Rockford, IL). Equivalent protein
extracts (15–50 mg) from each sample were electrophoresed on 8–15% sodium dodecyl
sulfate polyacrylamide gel electrophoresis mini gels. Proteins were transferred onto Hybond
nitrocellulose (Amersham, Piscataway, NJ) in a Bio-Rad Trans blot apparatus.
Nitrocellulose matrices were preblocked with 3% nonfat milk powder in PBS and 0.05%
Tween-20 for 1 hour at room temperature. After PBS–Tween washes, preblocked matrices
were incubated with appropriate dilution of primary antibody. Reactive bands were
visualized specific bands by enhanced chemiluminescence ECL (Pierce Biotechnology).
Clonogenic assay
DRO81-1 cells were cultured into 60-mm plates (300 cells/plate), then left in the incubator
overnight to attach. Cells were treated with withanolides for 72 hours at 37°C in a
humidified atmosphere of 95% air and 5% CO2. After treatment media was removed and
fresh media without drug was added. Cells incubated for 2 weeks to allow the formation of
macroscopic colonies. Media was changed 3 times a week. The cells were then stained with
Coomassie blue. At least 2 independent experiments, each using triplicate plates, were
performed for each cell line. Photographic documentation was recorded.
Statistical analysis
All in vitro data points were run in triplicate and expressed as a mean values ± standard error
of the mean. Raw data were analyzed by a Student’s unpaired t-test and Fisher exact tests
using a standard statistical analysis software package (SPSS version 17.0; SPSS Inc,
Chicago, IL); P < .05 was defined as significant.
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Withanolides impair MTC cell growth in part through induction of apoptosis
DRO81-1, TT-cells, and TPC1 cells were incubated with each of the drugs structurally listed
in Figure 1 for 72 hours (0.03–20 mmol/L) and cell viability was determined using MTS dye
reduction assay. Half maximal inhibitory concentration (IC50) values were determined for
each compound in all 3 cell-lines tested and are tabulated in the Table. Of all the compounds
tested, 17-AAG was the most potent in all cell-lines with an average IC50 in MTC 18 ± 4
nmol/L. All of the withanolides tested demonstrated significant potency against MTC cells
except for WGD, which structurally lacks the double bond in the A-ring of the molecule and
results in a loss of anticancer activity (structure–activity–relationship; data not shown). The
remaining withanolides demonstrated excellent potency in DRO81-1 MTC cells compared
with the targeted TKIs, but were less potent than vandetanib and cabozantinib in TT cells.
Addition of acetyl groups to the withalongolide A (WGA) molecule as noted with
withalongolide B 4-acetate (WGB-MA; a mono-acetyl analog), withalongolide B 4,19-
diacetate (WGB-DA, a di-acetyl analog) and withalongolide A 4,19,27-triacetate (WGA-
TA, a tri-acetyl analog), resulted in increased potency compared with the parent molecule
WGA. This was observed in all 3 cell-lines. Comparing the tri-acetyl and mono-acetyl
analogs, WGA-TA was significantly more potent than WGB-MA in each cell line tested (P
< .01). From this initial cell viability analysis, a ranking of potency for the withanolides
from least potent to most potent would include WGD, WGA, WA, WGB-MA, WGB-DA,
and WGA-TA. Owing to its stability and consistency of growth in vitro compared with TT
cells, further mechanistic studies were carried out using DRO81-1 cells.
Withanolides promote cell cycle arrest in MTC cells
We next examined that the effect of novel withanolides on modulation of cell cycle
progression in MTC cells. WGA induced a shift in cell cycle arrest from G0/G1 arrest to
G2/M arrest in DRO81-1 cells at 6.0 μmol/L for 24 hours and both at 3.0 and 6.0 μmol/L for
48 hours treatment as noted by PI staining peaks on flow cytometry (Fig 2, A). This shift
with treatment to G2/M arrest was also observed with WGB-MA and graphed quantitatively
in Figure 2, B. After 48 hours WGA treatment at 3 μmol/L there was a shift in G2/M arrest
from 20% to 35% of cells arrested at this checkpoint, whereas at 6 μmol/L this shift
increased to 40% of cells in G2/M (P <.01 compared with controls). Similarly, at 48 hours
both 1 and 3 μmol/L WGB-MA resulted in an increase in G2/M arrest from 25% to 42% of
cells arrested at this checkpoint (P < .01). WGB-DA also induced G2/M cell-cycle arrest in
MTC cells. After 24 hours of treatment, WGB-DA treatment induced G2/M shift from 23%
to 50% and 40% at 1 and 3 μmol/L. Similar results were obtained with MTC cells were
treated with WGB-DA for 48 hours (Fig 2, B).
Withanolides induced apoptosis in MTC cells
To explore the mechanism of withanolide-induced growth suppression, we examined the
effect of these novel compounds on the induction of apoptosis in MTC cells. Initial
evaluation was performed with annexin V/PI staining on flow cytometry and confirmed with
caspase 3 activation and poly-ADP ribose polymerase (PARP) cleavage on Western blot
analysis. WGA induced apoptosis in MTC cells at 3 and 6 μmol/L for 24 hours (5.1% and
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12.0%, respectively) and 48 hours (12.2% and 49%, respectively; P < .001; Fig 3, A and D).
Similarly WGB-MA induced apoptosis at 1 and 3 μmol/L in MTC cells at 24 hours (3% and
22%, respectively) and at 48 hours (28% and 82%, respectively; P < .001; Fig 3, B and D).
WGB-DA was the most potent withanolide for inducing apoptosis in MTC cells. At 1 and 3
μmol/L WGB-DA in MTC cells at 24 hours gated 11% and 46% of cells toward apoptotic
cell death, respectively, and at 48 hours this increased to 68% of cells undergoing apoptosis
at 1 μmol/L and 83% of cells undergoing apoptosis at 3 μmol/L (P < .001; Fig 3, C and D).
To confirm these results the levels of cleaved caspase 3 and the endogenous caspase 3
substrate, PARP, were determined by Western blot analysis of cells treated for 24 hours. Fig
3, E shows that WGB induced cleavage of caspase at 6 μmol/L concentration after 24 hours
treatment, whereas the more potent withanolides WGB-MA and WGB-DA activated caspase
3 and cleaved PARP starting at 1 μmol/L drug levels and peaking around 3 μmol/L of drug.
Similarly, the effect of axitinib, vandetanib- and XL184-treated DRO81-1 cells
demonstrated that these TKIs slightly induced caspase activation and PARP cleavage but
this occurred less robustly than observed with the novel withanolide compounds (Fig 3, E).
Withanolides promote inhibition of clonogenic growth
Clonogenic assay was performed to determine the long-term toxicity effect of withanolides
on MTC cells. Pulse-exposure of DRO81-1 cells for 3 days to either 1 μmol/L WGA, 250
nmol/L WGB-MA, or 250 nmol/L WGB-DA irreversibly inhibited 80% clonogenic growth
compared with untreated DRO81-1 cells (Fig 4).
Withanolides suppressed activation of RET and Akt/mTOR pathway
To elucidate the mechanism by which withanolides induce apoptosis and suppress MTC cell
viability and growth, we evaluated by Western blot analysis the effects of these drugs on
several key regulatory pathways and proteins in MTC cells, specifically activation of RET,
the MAP kinase pathway (ERK1/2) and the Akt/mTOR pathway. Because alterations in
protein expression in response to drug treatment may be both time- and concentration-
dependent, we evaluated each drug at multiple doses (above and below IC50 levels) at 12
hours and at 24 hours treatment. Comparisons of expressions of these signaling proteins are
shown for each withanolide drug in Fig 5. WGA, WGB-MA, and WGB-DA each
demonstrated a consistent pattern related to their mechanistic effects on MTC signaling
pathways. Each of these withanolides downregulated total and phospho-RET expression
levels as well as total and phospho-mTOR expression levels and total and phospho-Akt
levels. Downstream mTOR signaling was also effected in these withanolide-treated cells.
Because mTOR modulates activity of downstream 4E-BP1 and p70S6kinase to regulate
RNA translation and protein synthesis respectively, these proteins were evaluated in
response to drug treatment. All 3 withanolides demonstrated inhibition of 4E-BP1,
phospho-4E-BP1, p70S6kinase, and phospho-p706Skinase at 24 hours drug treatment with
downregulation occurring at 500 nmol/L concentrations, which is at or below IC50 drug
levels in DRO81-1 cells (Fig 5). ERK1/2 expression levels, however, were increased with
drug treatment. Inhibition of both RET activity and the Akt/mTOR pathway occurred as
early as 12 hours after treatment. WGD, which has the lowest potency in vitro and lacks the
double bond in the A-ring (which conveys activity), demonstrated up-regulation of RET,
Akt, ERK1/2, and the mTOR pathway, including 4E-BP1 and p70S6 kinase, which
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coincided with its lack of in vitro growth inhibition or induction of apoptosis (Fig 5, D).
Finally, vandetanib and cabozantinib (clinical TKIs used in MTC) were evaluated for their
effects on the same regulatory proteins in MTC cells (Fig 6). Both of these drugs inhibited
phospho- and total RET expression levels at 24 hours, although significantly less robustly
than noted with WGB-MA or WGB-DA withanolide treatment (P < .01 based on
densiometry measurements of comparative protein bands). Interestingly, these targeted
therapies did not inhibit mTOR or its downstream constituent p-70S6 kinase, although only
at 3 μmol/L (10 times the IC50 level) did vandetanib slightly downregulate 4E-BP1 levels.
Both TKIs markedly downregulated ERK1/2 and phospho-ERK expression levels while
upregulating Akt expression levels in a dose-dependent manner.
DISCUSSION
For patients with unresectable or advanced MTC, a targeted therapy trial has been an
approach of choice when such treatments are available. With cabozantinib completing its
Phase III international trial and vandetanib’s recent US Food and Drug Administration
approval for use in MTC, these targeted agents are the most commonly used clinically.17
Outcomes from these studies, however, are modest at best and each of these drugs carry
moderate toxicity profiles.
Natural products have played a significant role in the discovery and development of new
anticancer agents, and represent a rich source of biologically active compounds. More than
80% of anticancer drugs introduced from January 1981 to October 2008 were natural
products, semi-synthetic analogs, or synthetic compounds based on natural product
pharmacophores.18 Withanolides are naturally occurring C-28-steroidal lactones built on an
intact or rearranged ergostane scaffold in which C-22 and C-26 are appropriately oxidized to
form a δ-lactone ring on the 9-carbon side chain.19 These compounds possess various
biological activities in vitro and in vivo, including antimicrobial, radiosensitizing,
antineoplastic, and cytotoxic effects.20–22 Although recent studies have demonstrated that
WA suppresses the growth of human cancer cell lines in vitro and in vivo by causing
apoptosis,15 the precise mechanism, including the signals and the pathways by which WA
induces cell death, is not fully understood. Our group has demonstrated that WA inhibits
MTC growth in vivo suppressing RET phosphorylation in the tumors as well as inhibiting
calcitonin secretion.15 This compound did not result in weight loss or any clinical toxicity in
vivo and has good oral bioavailability.
In the current experiments, we demonstrated that 3 novel withanolide compounds from the
Physalis plant demonstrated potent activity against MTC cells in vitro with IC50 levels for
acetylated analogs WGB-MA and WGB-DA in the mid-nanomolar range, comparable with
the potency of targeted TKIs such as vandetanib and cabozantinib. Treatment of MTC with
withanolides significantly irreversibly reduced clonogenic formation. Their mechanism of
action for this antiproliferative effect involves several processes including induction of
apoptosis, which was significantly enhanced with the acetylated analogs WGB-MA and
WGB-DA and involved >60% of cells at 1 μmol/L WGB-DA and 83% of cells at 3 μmol/L
of drug. These compounds also affect cell-cycle arrest, with significant shift of cells into
G2/M arrest, as reported with WA.21
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Given the high apoptotic rate with treatment, we investigated several key regulatory proteins
in MTC cells. The RET proto-oncogene is activated in MTC, leading to activation of the
RAS/RAF/MEK/ERK signaling pathway. Mutant RET with representative MEN2A
mutation at Cys-634 (RET-MEN2A) has been shown to activate PI3 kinase/Akt pathway.23
Furthermore, a recent study by Kouvaraki et al24 demonstrated that mTOR is highly active
in MTC cells. Because mTOR signaling controls protein synthesis through regulation of
translation initiation, identifying small molecules that target the mTOR pathway represents a
promising target for investigational therapy in MTC patients. The present study shows that
novel withanolides WGA, WGB-MA, and WGB-DA reduce both RET and Akt/mTOR
activation in MTC cells with inhibition of mTOR RNA translation through knockdown of
4E-BP1. This mechanism is unique from TKIs like ventatenib or cabozantinib, which knock
down RET and the MAP kinase pathway but do not affect the mTOR pathway. These TKIs
upregulate Akt expression levels, which may explain in part why apoptosis is not seen as
robustly in MTC cells with these therapies. These experiments are the first to identify this
unique mechanism of action of withanolide compounds in MTC cells. Because the novel
withanolide molecules WGA, WGB-MA, and WGB-DA work on different key regulatory
pathways than TKIs in MTC cells, there may be a role for synergy or combination therapies
of withanolides with these targeted TKIs. With similar mechanism to their parent molecule,
WA, these novel natural withanolide analogs have potent anticancer activity in vitro,
whereas WA itself has now progressed into a phase I clinical trial in India in patients with
advanced osteosarcomas.25 Overall, these novel withanolides demonstrate excellent potency
and anticancer activity in MTCs in vitro downregulating both RET and mTOR activity.
Ongoing in vivo efficacy and toxicity studies will better evaluate their clinical potential.
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Comparative chemical structures of withanolides and tyrosine kinase inhibitors tested.
Chemical structures are included for WA, WGA, WGA-TA, WGD, WGB-MA, WGB-DA,
axitinib, vandetanib, cabozantinib, and 17-AAG.
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Novel withanolides induce G2/M cell-cycle arrest in MTC cells. A, PI staining by flow
cytometry of DRO81-1 cells exposed to WGA cells at concentrations of 1–6 μmol/L for 24
and 48 hours. Of note there is a significant shift in cell-cycle arrest with an increase in the
size of the G2/M peak with increasing dose of WGA treatment at 48 hours. B, Bar graphs
with quantitative shifts in the cell cycle of DRO81-1 cells treated with either WGA, WGB-
MA, or WGB-DA for 24 or 48 hours. The shift was significant to G2/M arrest with
withanolide treatment. (Color version of figure is available online.)
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Novel withanolides induce apoptosis in MTC cells. Dot-blot flow cytometry data for co-
staining with Annexin V and PI after treatment with different concentrations of 3 novel
withanolides, (A) WGA, (B) WGB-MA, and (C) WGB-DA. Significant apoptosis was
observed at 6 μmol/L WGA, and 1 μmol/L WGB-MA, and WGB-DA. D, Quantitative
apoptosis of MTC cells treated with these withanolides for 24 and 48 hours. More than 80%
of cells were gated toward apoptotic cell death with only 3 μmol/L exposure of WGB-DA.
E, Confirmation of apoptosis by Western Blot analysis, demonstrating activation of caspase
3 and cleavage of PARP in a dose-dependent manner, starting at 1 μmol/L of withanolide
drug. This effect is less robust with the TKI drug compounds at similar concentrations.
(Color version of figure is available online.)
Samadi et al. Page 12























Novel withanolides inhibit clonogenic growth in MTC cells. Inhibition of clonogenic growth
formation by WGA at 1 μmol/L drug concentration; WGB-MA and WGB-DA inhibited
growth at only 250 nmol/L concentrations, consistent with IC50 values. This assay suggests
that the anticancer effects of withanolides on MTC cells are longer term and not easily
reversible. (Color version of figure is available online.)
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Comparison of the effects of withanolide drug treatment on the expression of key regulatory
proteins involved in MTC cells using Western Blot Analysis. (A) WGA effects on protein
expression. (B) Expression changes from WGB-MA. (C) WGB-DA mechanistic actions. (D)
WGD actions. The active withanolides WGA, WGB-MA, and WGB-DA down-regulated
RET, p-RET, mTOR, p-mTOR, 4E-BP1, and Akt expression in a dose-dependent manner.
These data indicate that withanolides not only knock down RET activity, but also inhibit the
Akt/mTOR regulatory pathway, which may account in part for their robust induction of
apoptosis in MTC cells. WGD was inactive on MTS assay owing to loss of the double bond
in the A-ring of the structure. This compound upregulated mTOR, Akt, and ERK as well as
RET activity.
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Comparison of the effects of vandetanib and cabozantinib drug treatment on the expression
of key regulatory proteins involved in MTC cells using Western blot analysis. Both TKIs
were evaluated for their effects on similar regulatory proteins studied in Fig 5. Withanolides
differ from TKIs in their mechanism of action in that the 2 TKIs tested do not inhibit the
Akt/mTOR signaling pathway, but rather downregulate RET activity and the MAP kinase
pathway. These differences in action suggest a potential for synergy or combination therapy.
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Table




WA 1.09 2.76 0.48
WGA 2.85 2.17 0.29
WGD 5.84 17.0 4.39
WGB-MA 0.96 1.31 0.077
WGB-DA 0.58 0.86 0.030
WGA-TA 0.27 1.03 0.039
Axitinib 1.18 0.78 0.95
Vandetanib 2.38 0.25 0.27
XL184 2.64 0.36 0.16
17-AAG 0.012 0.024 0.015
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